533 related articles for article (PubMed ID: 23027419)
1. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G
Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic mechanisms in schizophrenia.
Tsai G; Coyle JT
Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
[TBL] [Abstract][Full Text] [Related]
3. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
4. Is NMDA receptor hypofunction in schizophrenia associated with a primary hyperglutamatergic state?
Shim SS; Adityanjee
Arch Gen Psychiatry; 2002 May; 59(5):466-7; author reply 467-8. PubMed ID: 11982452
[No Abstract] [Full Text] [Related]
5. Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.
Jeevakumar V; Kroener S
Cereb Cortex; 2016 Mar; 26(3):1117-29. PubMed ID: 25477370
[TBL] [Abstract][Full Text] [Related]
6. Schizophrenia: Basic and Clinical.
Coyle JT
Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
[TBL] [Abstract][Full Text] [Related]
7. Glutamate and schizophrenia: beyond the dopamine hypothesis.
Coyle JT
Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
[TBL] [Abstract][Full Text] [Related]
8. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
Coyle JT; Tsai G; Goff D
Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
10. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
11. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
Coyle JT
Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
13. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis.
Iasevoli F; Polese D; Ambesi-Impiombato A; Muscettola G; de Bartolomeis A
Neurosci Lett; 2007 Apr; 416(1):1-5. PubMed ID: 17317002
[TBL] [Abstract][Full Text] [Related]
14. Reviewing the ketamine model for schizophrenia.
Frohlich J; Van Horn JD
J Psychopharmacol; 2014 Apr; 28(4):287-302. PubMed ID: 24257811
[TBL] [Abstract][Full Text] [Related]
15. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
Kolomeets NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
[TBL] [Abstract][Full Text] [Related]
16. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.
Gonzalez-Burgos G; Lewis DA
Schizophr Bull; 2012 Sep; 38(5):950-7. PubMed ID: 22355184
[TBL] [Abstract][Full Text] [Related]
18. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic theories of schizophrenia.
Javitt DC
Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
[TBL] [Abstract][Full Text] [Related]
20. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
Moghaddam B; Krystal JH
Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
